Troeger, J. S. et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 143, 1073–1083. e1022 (2012).
Hu, M. et al. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat. Commun. 10, 2993 (2019).
Fallowfield, J. A. et al. Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Hepatology 59, 1492–1504 (2014).
Tacke, F. & Zimmermann, H. W. Macrophage heterogeneity in liver injury and fibrosis. J. Hepatol. 60, 1090–1096 (2014).
Ramachandran, P. et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc. Natl Acad. Sci. USA 109, E3186–E3195 (2012).
Pellicoro, A., Ramachandran, P., Iredale, J. P. & Fallowfield, J. A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14, 181–194 (2014).
Francis, H. et al. Regulation of the extrinsic apoptotic pathway by microRNA-21 in alcoholic liver injury. J. Biol. Chem. 289, 27526–27539 (2014).
Chen, S. A. et al. The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration. Pharma. Res 10, 834–838 (1993).
Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
Friedman, S. L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125–172 (2008).
Hu, M. & Huang, L. Nanomaterial manipulation of immune microenvironment in the diseased liver. Adv. Funct. Mater. 29, 1805760 (2019).
Kushiyama, T. et al. Alteration in the phenotype of macrophages in the repair of renal interstitial fibrosis in mice. Nephrology 16, 522–535 (2011).
Ma, P. F. et al. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice. J. Hepatol. 67, 770–779 (2017).
Kern, K. et al. CD200 selectively upregulates prostaglandin E2 and D2 synthesis in LPS-treated bone marrow-derived macrophages. Prostag. Oth. Lipid Mediat. 133, 53–59 (2017).
Wang, M. et al. Chronic alcohol ingestion modulates hepatic macrophage populations and functions in mice. J. Leukoc. Biol. 96, 657–665 (2014).
Liaskou, E. et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology 57, 385–398 (2013).
Zimmermann, H. W. et al. Functional contribution of elevated circulating and hepatic non-classical CD14 + CD16 + monocytes to inflammation and human liver fibrosis. PloS ONE 5, e11049 (2010).
Krenkel, O. & Tacke, F. Liver macrophages in tissue homeostasis and disease. Nat. Rev. Immunol. 17, 306–321 (2017).
Hanna, R. N. et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C− monocytes. Nat. Immunol. 12, 778–785 (2011).
Mildner, A. et al. Genomic characterization of murine monocytes reveals C/EBPβ transcription factor dependence of Ly6C− cells. Immunity 46, 849–862. e847 (2017).
Palumbo-Zerr, K. et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis. Nat. Med. 21, 150–158 (2015).
Hsu, S. Y. et al. Activation of orphan receptors by the hormone relaxin. Science 295, 671–674 (2002).
Maruoka, H. et al. Dibutyryl-cAMP up-regulates Nur77 expression via histone modification during neurite outgrowth in PC12 cells. J. Biochem. 148, 93–101 (2010).
Lough, J., Rosenthall, L., Arzoumanian, A. & Goresky, C. A. Kupffer cell depletion associated with capillarization of liver sinusoids in carbon tetrachloride-induced rat liver cirrhosis. J. Hepatol. 5, 190–198 (1987).
Simons, M. & Raposo, G. Exosomes—vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 21, 575–581 (2009).
Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659 (2007).
Kim, K. M., Abdelmohsen, K., Mustapic, M., Kapogiannis, D. & Gorospe, M. RNA in extracellular vesicles. WIREs RNA 8, e1413 (2017).
Tokar, T. et al. mirDIP 4.1—integrative database of human microRNA target predictions. Nucleic Acids Res. 46, D360–D370 (2017).
Zhang, P. et al. The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. Nat. Med. 24, 84–94 (2018).
Liles, J. T. et al. ASK1 contributes to fibrosis and dysfunction in models of kidney disease. J. Clin. Investig. 128, 4485–4500 (2018).
Singh, S., Simpson, R. L. & Bennett, R. G. Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α). J. Biol. Chem. 290, 950–959 (2015).
Singh, S. & Bennett, R. G. Relaxin signaling activates peroxisome proliferator-activated receptor gamma. Mol. Cell. Endocrinol. 315, 239–245 (2010).
Hazra, S., Miyahara, T., Rippe, R. A. & Tsukamoto, H. PPAR gamma and hepatic stellate cells. Comp. Hepatol. 3, S7 (2004).
Wei, J. et al. PPARγ downregulation by TGF-β in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PloS ONE 5, e13778 (2010).
Chibon, F. et al. ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14–q15 and 6q23 amplifications. Genes Chromosomes Cancer 40, 32–37 (2004).
Tang, X. et al. An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARγ, adipogenesis, and insulin-responsive hexose transport. Proc. Natl Acad. Sci. USA 103, 2087–2092 (2006).
Xiong, J. et al. hnRNPU/TrkB defines a chromatin accessibility checkpoint for liver injury and nonalcoholic steatohepatitis pathogenesis. Hepatology 71, 1228–1246 (2020).
Matsumoto, M. et al. An improved mouse model that rapidly develops fibrosis in non‐alcoholic steatohepatitis. Int. J. Exp. Pathol. 94, 93–103 (2013).
Bani, D., Bigazzi, M., Masini, E., Bani, G. & Sacchi, T. B. Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets. Lab. Invest. 73, 709–716 (1995).
Erikson, M. S. & Unemori, E. N. in Relaxin 2000 (eds Tregear G.W., Ivell R., Bathgate R.A. & Wade J.D.) 373–381 (Springer, 2001).
Amitrano, L., Guardascione, M. A., Brancaccio, V. & Balzano, A. Coagulation disorders in liver disease. Semin. Liver Dis. 22, 83–96 (2002).
Rios, R., Sangro, B., Herrero, I., Quiroga, J. & Prieto, J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am. J. Gastroenterol. 100, 1311 (2005).
Berres, M. L. et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J. Clin. Investig. 120, 4129–4140 (2010).
Mitchell, C. et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am. J. Pathol. 174, 1766–1775 (2009).
Lefebvre, E. et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PloS ONE 11, e0158156 (2016).
Banerjee, R., Tyagi, P., Li, S. & Huang, L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer 112, 693–700 (2004).
Constandinou, C., Henderson, N. & Iredale, J. P. in Fibrosis Research: Methods and Protocols (eds Varga, J., David A. Brenner, D. A. & Phan, S. H.) 237–250 (Springer, 2005).
Wang, Y. et al. Nanoparticle-mediated HMGA1 silencing promotes lymphocyte infiltration and boosts checkpoint blockade immunotherapy for cancer. Adv. Funct. Mater. 28, 1802847 (2018).
Teerlink, J. R. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381, 29–39 (2013).
Ying, W., Cheruku, P. S., Bazer, F. W., Safe, S. H. & Zhou, B. Investigation of macrophage polarization using bone marrow derived macrophages. J. Vis. Exp. 76, e50323 (2013).
